Sophisticated new genetic tests face an uncertain future — unless they can win clear-cut approval from regulators, insurers and, most importantly, doctors. Virginia Gewin reports.
This is a preview of subscription content, log in via an institution to check access.
Related links
Related links
Related links in Nature Research
Opinion: The US Food and Drug Administration perspective on cancer biomarker development
A regulatory perspective on in vitro diagnostics
Three barriers to innovative diagnostics
Related external links
Rights and permissions
About this article
Cite this article
Crunch time for multiple-gene tests. Nature 445, 354–355 (2007). https://doi.org/10.1038/445354a
Published:
Issue Date:
DOI: https://doi.org/10.1038/445354a
- Springer Nature Limited
This article is cited by
-
Nutzung von Markersystemen in der Behandlung des Harnblasenkarzinoms
Der Urologe (2011)